TDEVs produce tumor‐specific antigens that may also be recognized and processed by DCs, leading to the activation of DCs and the stimulation of antigen‐specific CD8+ T lymphocytes, which in turn exhibit antitumor effects. The gene discussed is CD8A; the disease is neoplasm.